Eton Pharmaceuticals and Aquestive Therapeutics announced a U.S. licensing agreement for LIBERVANT buccal film, targeting a U.S. market opportunity exceeding $450 million. The deal is expected to advance Eton's rare disease portfolio and provide a near-term growth opportunity in neurology.